Compare NetEase Inc (NTES) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs GeneDx Holdings Corp — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: NetEase Inc is far larger — about 37.7× GeneDx Holdings Corp's market cap, and NetEase Inc pays a 2.45% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and GeneDx Holdings Corp for 19 Days on average.
| NTES | WGS | |
|---|---|---|
Market Cap | $76.09B | $2.02B |
Volume | 486,447 | 734,640 |
Sector | Technology | Health |
52-Week High | $152.85 | $167.51 |
52-Week Low | $109.26 | $34.51 |
Typical Hold Time | 73 Days | 19 Days |
Enterprise Value | $51.81B | $2.05B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.6, down 0.84% on the day, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 revenue growth of 8% year-over-year but missed EPS expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Analyst sentiment remains bullish with an 81.82% buy rating and a consensus price target of $168.00, suggesting significant upside potential from current levels.
The outlook for NTES is positive based on solid profitability and analyst confidence, though risks include earnings volatility and competitive pressures in the gaming sector. Investment opportunity lies in valuation expansion if the company can consistently meet earnings expectations and sustain its high margins. Key risks are execution missteps and broader market sentiment toward Chinese tech stocks.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
